Abstract
We review fundamental processes, such as mutation, oxidative stress, and inflammation that are critical for carcinogenesis and provide specific molecular targets for new chemopreventive agents. New information from molecular biology studies has identified such targets, including regulatory molecules such as Nrf2 (nuclear factor erythroid 2-related factor 2), epidermal growth factor receptor kinases, phosphatidylinositol 3-kinase, components of the Janus kinase–signal transducers and activators of transcription (JAK–STAT) pathway, nuclear factor-κB, and cyclin D. The development of new drugs for the control of these targets that are both safe and effective will be important for the future of cancer chemoprevention.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bishop JM (1997) Cancer: what should be done? Science 278: 995
Fisher B et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P–1 study. J Natl Cancer Inst 98: 1371–1388
Martino S et al. (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96: 1751–1761
Jemal A et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 54: 10–30
Sporn MB and Suh N (2002) Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2: 537–543
Solomon SD et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080
Bresalier RS et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102
Hussain SP et al. (2003) Radical causes of cancer. Nat Rev Cancer 3: 276–285
Marnett LJ (2000) Oxyradicals and DNA damage. Carcinogenesis 21: 361–370
Sporn MB and Roberts AB (1986) Peptide growth factors and inflammation, tissue repair, and cancer. J Clin Invest 78: 329–332
Coussens LM and Werb Z (2002) Inflammation and cancer. Nature 420: 860–867
Balkwill F et al. (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211–217
Mann JR et al. (2005) Mechanisms of disease: inflammatory mediators and cancer prevention. Nat Clin Prac Oncol 2: 202–210
Laird PW (2005) Cancer epigenetics. Hum Mol Genet 14: R65–R76
Lund AH and van Lohuizen M (2004) Epigenetics and cancer. Genes Dev 18: 2315–2335
Feinberg AP and Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4: 143–153
Prestera T et al. (1993) The electrophile counterattack response: protection against neoplasia and toxicity. Adv Enzyme Regul 33: 291–296
Kwak M-K et al. (2002) Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat Res 555: 133–148
Talalay P et al. (2003) Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis. Adv Enzyme Regul 43: 121–134
Zhang Y and Gordon GB (2004) A strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathway. Mol Cancer Ther 3: 885–893
Lee J-S and Surh Y-J (2005) Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 224: 171–184
Nguyen T et al. (2003) Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 43: 233–260
Dinkova-Kostova A et al. (2005) Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA 102: 4584–4589
Liby K et al. (2005) The synthetic triterpenoids, CDDO and CDDO-Imidazolide are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 65: 4789–4798
Vodovotz Y (1997) Control of nitric oxide production by transforming growth factor-β1: mechanistic insights and potential relevance to human disease. Nitric Oxide 1: 3–17
Ning W et al. (2002) TGF-β1 stimulates HO-1 via the p38 mitogen-activated protein kinase in A549 pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 283: L1094–L1102
Suh N et al. (2003) Synthetic triterpenoids enhance transforming growth factor-β/Smad signaling. Cancer Res 63: 1371–1376
Otterbein LE et al. (2000) Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nature Med 6: 422–428
Ryter SW et al. (2004) Carbon monoxide: to boldly go where NO has gone before. Sci STKE 2004: RE6
Poynter JN et al. (2005) Statins and the risk of colorectal cancer. N Engl J Med 352: 2184–2192
Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685–1695
Grosser N et al. (2004) Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochem Biophys Res Commun 325: 871–876
Lee T-S et al. (2004) Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 110: 1296–1302
Madonna R et al. (2005) Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. J Biol Chem 280: 13503–13511
O'Shaughnessy JA et al. (2002) Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8: 314–346
Sporn MB (1991) Carcinogenesis and cancer: different perspectives on the same disease. Cancer Res 51: 6215–6218
Sledge GW Jr (2003) Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer. Semin Oncol 30: 19–21
Giaccone G (2005) Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23: 3235–3242
Lu C et al. (2003) Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95: 1825–1833
Luo J et al. (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257–262
Sansal I and Sellers WR (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 14: 2954–2963
Tsao AS et al. (2003) Increased phospho-Akt (SER483) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 12: 660–664
Balsara BR et al. (2004) Frequent activation of Akt in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053–2059
Thompson JE and Thompson CB (2004) Putting the Rap on Akt. J Clin Oncol 22: 4217–4226
Sekulic A et al. (2002) A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60: 3504–3513
Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2: 740–749
Pikarsky E et al. (2004) NF-κB functions as a tumor promoter in inflammation-associated cancer. Nature 431: 461–466
Greten FR et al. (2004) IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285–296
Darnell JE Jr (2005) Validating Stat3 in cancer therapy. Nat Med 11: 595–596
Clevenger CV (2004) Roles and regulation of Stat family transcription factors in human breast cancer. Am J Pathol 165: 1449–1460
Yu H and Jove R (2004) The Stats of cancer—new molecular targets come of age. Nat Rev Cancer 4: 97–105
O'Shea JJ et al. (2004) A new modality for immunosuppression: targeting the JAK/Stat pathway. Nat Rev Drug Disc 3: 555–564
Petty WJ et al. (2003) Cyclin D1 as a target for chemoprevention. Lung Cancer 41 (Suppl): S155–S161
Ma Y et al. (2005) Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res 65: 6476–6483
Leaf C (2004) Why we're losing the war on cancer (and how to win it). Fortune 149: 77–96
Rendi MH et al. (2004) The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. Cancer Res 64: 3566–3571
Sporn MB (1996) The war on cancer. Lancet 347: 1377–1381
Nathan C (2002) Points of control in inflammation. Nature 420: 846–852
Marnett LG et al. (2003) Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J Clin Invest 111: 583–593
Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868–874
Beal MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 991: 120–131
McGeer EG and McGeer PL (2003) Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 27: 741–749
Nguyen T et al. (2005) Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem [10.1074/jbc.M503074200]
Eggler AL et al. (2005) Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc Natl Acad Sci USA 102: 10070–10075
Acknowledgements
We thank Carl Nathan, Paul Talalay, Thomas Kensler, Anita Roberts, and Clifton Leaf for valuable discussions. Megan Padgett has provided expert assistance in the preparation of this review. Supported by grants from the National Cancer Institute (CA-78814), the National Foundation for Cancer Research, and members of the Dartmouth College Class of 1934.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Sporn, M., Liby, K. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat Rev Clin Oncol 2, 518–525 (2005). https://doi.org/10.1038/ncponc0319
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0319
This article is cited by
-
Marine-derived pipeline anticancer natural products: a review of their pharmacotherapeutic potential and molecular mechanisms
Future Journal of Pharmaceutical Sciences (2021)
-
Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay
Scientific Reports (2019)
-
Epigenome-based cancer risk prediction: rationale, opportunities and challenges
Nature Reviews Clinical Oncology (2018)
-
Chemopreventive effect of 18β-glycyrrhetinic acid via modulation of inflammatory markers and induction of apoptosis in human hepatoma cell line (HepG2)
Molecular and Cellular Biochemistry (2016)
-
Genetic and epigenetic cancer chemoprevention on molecular targets during multistage carcinogenesis
Archives of Toxicology (2016)